Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.

Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE.

J Urol. 2018 Sep;200(3):564-572. doi: 10.1016/j.juro.2018.03.004. Epub 2018 Mar 7.

PMID:
29524506
2.

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).

Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR.

PLoS One. 2017 Oct 10;12(10):e0185535. doi: 10.1371/journal.pone.0185535. eCollection 2017.

3.

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.

Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC.

Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.

PMID:
28988753
4.

Standardizing Methodology for Research with Uneven Terrains Focused on Dynamic Balance During Gait.

Coleman TD, Lawrence HJ, Childers WL.

J Appl Biomech. 2016 Dec;32(6):599-602. Epub 2016 Sep 6.

PMID:
27619351
5.

Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.

Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA.

Oncotarget. 2016 Jun 7;7(23):33855-65. doi: 10.18632/oncotarget.8944.

6.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ.

Urology. 2016 Mar;89:69-75. doi: 10.1016/j.urology.2015.12.008. Epub 2015 Dec 23.

7.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW.

Rev Urol. 2014;16(4):172-80.

8.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

9.

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M.

PLoS One. 2014 Feb 25;9(2):e89518. doi: 10.1371/journal.pone.0089518. eCollection 2014.

10.

Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

O'Donnell P, Ferguson J, Shyu J, Current R, Rehage T, Tsai J, Christensen M, Tran HB, Chien SS, Shieh F, Wei W, Lawrence HJ, Wu L, Schilling R, Bloom K, Maltzman W, Anderson S, Soviero S.

BMC Cancer. 2013 Apr 27;13:210. doi: 10.1186/1471-2407-13-210.

11.

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ, Gonzalez de Castro D.

J Clin Pathol. 2013 May;66(5):381-5. doi: 10.1136/jclinpath-2012-201240. Epub 2013 Feb 5.

12.

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, de Castro DG.

PLoS One. 2013;8(1):e53733. doi: 10.1371/journal.pone.0053733. Epub 2013 Jan 10.

13.

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.

Gonzalez de Castro D, Angulo B, Gomez B, Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH, Lawrence HJ, Lopez-Rios F.

Br J Cancer. 2012 Jul 10;107(2):345-51. doi: 10.1038/bjc.2012.259. Epub 2012 Jun 19.

14.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A.

N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.

15.

Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC.

Arch Pathol Lab Med. 2012 Nov;136(11):1385-91. doi: 10.5858/arpa.2011-0505-OA. Epub 2012 Feb 14.

PMID:
22332713
16.

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.

Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ.

Diagn Mol Pathol. 2012 Mar;21(1):1-8. doi: 10.1097/PDM.0b013e31823b216f.

PMID:
22306669
17.

Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.

Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S, Lawrence HJ.

Virchows Arch. 2012 Feb;460(2):141-9. doi: 10.1007/s00428-011-1180-0. Epub 2011 Dec 16.

18.

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E.

Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280.

19.

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP.

Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.

20.

Transit-amplifying cell frequency and cell cycle kinetics are altered in aged epidermis.

Charruyer A, Barland CO, Yue L, Wessendorf HB, Lu Y, Lawrence HJ, Mancianti ML, Ghadially R.

J Invest Dermatol. 2009 Nov;129(11):2574-83. doi: 10.1038/jid.2009.127. Epub 2009 May 21.

21.

Rapid adhesion to collagen isolates murine keratinocytes with limited long-term repopulating ability in vivo despite high clonogenicity in vitro.

Strachan LR, Scalapino KJ, Lawrence HJ, Ghadially R.

Stem Cells. 2008 Jan;26(1):235-43. Epub 2007 Oct 11.

22.

Hoxa9/hoxb3/hoxb4 compound null mice display severe hematopoietic defects.

Magnusson M, Brun AC, Lawrence HJ, Karlsson S.

Exp Hematol. 2007 Sep;35(9):1421-8.

PMID:
17761289
23.

Nucleophosmin mutations in acute myeloid leukemia in children.

Lawrence HJ.

Leukemia. 2007 Sep;21(9):1849-50. No abstract available.

PMID:
17712359
24.

Evidence that the Pim1 kinase gene is a direct target of HOXA9.

Hu YL, Passegué E, Fong S, Largman C, Lawrence HJ.

Blood. 2007 Jun 1;109(11):4732-8. Epub 2007 Feb 27.

25.

Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia.

Lu CM, Wang E, Lawrence HJ.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):174-5. No abstract available.

PMID:
17213030
26.

Analysis of HSC activity and compensatory Hox gene expression profile in Hoxb cluster mutant fetal liver cells.

Bijl J, Thompson A, Ramirez-Solis R, Krosl J, Grier DG, Lawrence HJ, Sauvageau G.

Blood. 2006 Jul 1;108(1):116-22. Epub 2005 Dec 8.

27.

Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells.

Lawrence HJ, Christensen J, Fong S, Hu YL, Weissman I, Sauvageau G, Humphries RK, Largman C.

Blood. 2005 Dec 1;106(12):3988-94. Epub 2005 Aug 9.

28.

HOX genes: not just myeloid oncogenes any more.

Lawrence HJ, Fischbach NA, Largman C.

Leukemia. 2005 Aug;19(8):1328-30. No abstract available.

PMID:
15931267
29.

Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells.

Ferrell CM, Dorsam ST, Ohta H, Humphries RK, Derynck MK, Haqq C, Largman C, Lawrence HJ.

Stem Cells. 2005 May;23(5):644-55.

30.

Surgical management of gallbladder mucoceles in dogs: 22 cases (1999-2003).

Worley DR, Hottinger HA, Lawrence HJ.

J Am Vet Med Assoc. 2004 Nov 1;225(9):1418-22.

PMID:
15552319
31.

HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo.

Fischbach NA, Rozenfeld S, Shen W, Fong S, Chrobak D, Ginzinger D, Kogan SC, Radhakrishnan A, Le Beau MM, Largman C, Lawrence HJ.

Blood. 2005 Feb 15;105(4):1456-66. Epub 2004 Nov 2.

32.

HOXB6 protein is bound to CREB-binding protein and represses globin expression in a DNA binding-dependent, PBX interaction-independent process.

Shen W, Chrobak D, Krishnan K, Lawrence HJ, Largman C.

J Biol Chem. 2004 Sep 17;279(38):39895-904. Epub 2004 Jul 21.

33.

Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias.

Nguyen VH, Lawrence HJ.

J Clin Oncol. 2004 May 1;22(9):1767-9. No abstract available.

PMID:
15118009
34.

Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.

Vijapurkar U, Fischbach N, Shen W, Brandts C, Stokoe D, Lawrence HJ, Largman C.

Mol Cell Biol. 2004 May;24(9):3827-37.

35.

The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells.

Dorsam ST, Ferrell CM, Dorsam GP, Derynck MK, Vijapurkar U, Khodabakhsh D, Pau B, Bernstein H, Haqq CM, Largman C, Lawrence HJ.

Blood. 2004 Mar 1;103(5):1676-84. Epub 2003 Nov 6.

36.

Measuring stem cell frequency in epidermis: a quantitative in vivo functional assay for long-term repopulating cells.

Schneider TE, Barland C, Alex AM, Mancianti ML, Lu Y, Cleaver JE, Lawrence HJ, Ghadially R.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11412-7. Epub 2003 Sep 17.

37.

Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny.

Pineault N, Helgason CD, Lawrence HJ, Humphries RK.

Exp Hematol. 2002 Jan;30(1):49-57.

PMID:
11823037
38.

Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion.

Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G.

Blood. 2002 Jan 1;99(1):121-9.

39.

The HOX homeodomain proteins block CBP histone acetyltransferase activity.

Shen WF, Krishnan K, Lawrence HJ, Largman C.

Mol Cell Biol. 2001 Nov;21(21):7509-22.

40.

Positive and negative regulation of granulopoiesis by endogenous RARalpha.

Kastner P, Lawrence HJ, Waltzinger C, Ghyselinck NB, Chambon P, Chan S.

Blood. 2001 Mar 1;97(5):1314-20.

41.

Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.

Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Kömüves L, Buchberg AM, Largman C.

Leukemia. 1999 Dec;13(12):1993-9.

42.

HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells.

Shen WF, Rozenfeld S, Kwong A, Köm ves LG, Lawrence HJ, Largman C.

Mol Cell Biol. 1999 Apr;19(4):3051-61.

43.

Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes.

Izon DJ, Rozenfeld S, Fong ST, Kömüves L, Largman C, Lawrence HJ.

Blood. 1998 Jul 15;92(2):383-93.

44.

HOX homeobox genes exhibit spatial and temporal changes in expression during human skin development.

Stelnicki EJ, Kömüves LG, Kwong AO, Holmes D, Klein P, Rozenfeld S, Lawrence HJ, Adzick NS, Harrison M, Largman C.

J Invest Dermatol. 1998 Feb;110(2):110-5.

45.

Effects of HOX homeobox genes in blood cell differentiation.

Magli MC, Largman C, Lawrence HJ.

J Cell Physiol. 1997 Nov;173(2):168-77. Review.

PMID:
9365517
46.

AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins.

Shen WF, Montgomery JC, Rozenfeld S, Moskow JJ, Lawrence HJ, Buchberg AM, Largman C.

Mol Cell Biol. 1997 Nov;17(11):6448-58.

47.

The Abd-B-like Hox homeodomain proteins can be subdivided by the ability to form complexes with Pbx1a on a novel DNA target.

Shen WF, Rozenfeld S, Lawrence HJ, Largman C.

J Biol Chem. 1997 Mar 28;272(13):8198-206.

48.

Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis.

Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, Largman C.

Blood. 1997 Mar 15;89(6):1922-30.

49.

Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation.

Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, Largman C, Humphries RK.

Immunity. 1997 Jan;6(1):13-22.

50.

Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia.

Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK.

Mol Cell Biol. 1997 Jan;17(1):495-505.

Supplemental Content

Loading ...
Support Center